Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

52.51 -0.08 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,272,583
Open 52.89
Bid (Size) 52.51 (11)
Ask (Size) 54.61 (5)
Prev. Close 52.59
Today's Range 52.48 - 53.17
52wk Range 36.91 - 57.82
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Biotech Stocks to Avoid Like the Plague
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs. 
Via InvestorPlace
Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained
 
Via Benzinga

Performance

YTD
+7.16%
+7.16%
1 Month
-1.74%
-1.74%
3 Month
+9.74%
+9.74%
6 Month
+15.31%
+15.31%
1 Year
-1.39%
-1.39%

More News

Read More
2 Bear Market Defying Stocks to Buy in May
Via The Motley Fool
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
Via MarketBeat
Exposures Product Safety
Roche's Investigational Drug For Relapsing Multiple Sclerosis Reduces Brain Lesions, Data Shows
Via Benzinga
Peering Into Sanofi's Recent Short Interest
Via Benzinga
Sanofi (SNY) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Sanofi (NASDAQ: SNY) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Rebates or Patent Abuse? Eli Lilly, Novo Nordisk, and Sanofi CEOs Cross Swords with PBMs in Senate Hearing
Via Benzinga
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody
Via Benzinga
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns
Via Investor's Business Daily
What Wall Street Is Saying About Disney Ahead Of Earnings
Via Talk Markets
Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics
Via Benzinga
Earnings Outlook For Sanofi
Via Benzinga
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Via MarketBeat
7 Blue-Chip Stocks to Buy in May 2023
Via InvestorPlace
Why Regeneron Pharmaceuticals Shares Are Trading Lower Today
Via Benzinga
7 Stock Upgrades and Downgrades Alerts You Cannot Ignore
Via InvestorPlace
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Via Benzinga
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
Via Benzinga
Sanofi In-Licenses Pompe Disease Therapy From Privately-Held Maze Therapeutics For $150M Upfront
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Via Investor's Business Daily
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
Via Benzinga
Earnings Scheduled For April 27, 2023
Via Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.